Corsera Health is pursuing a vision of eliminating cardiovascular disease by pairing AI-enabled risk prediction with long-acting RNA interference therapeutics. Its lead program targets the two main drivers of atherosclerotic cardiovascular disease—elevated LDL-C and high blood pressure—using subcutaneously administered siRNA molecules that silence PCSK9 (COR-1004) and AGT (COR-2003). COR-1004 has begun dosing in a Phase 1 trial focused on safety, PCSK9 knockdown, and LDL-C reduction, with initial proof-of-concept data expected in 2026; the AGT program is slated to enter Phase 1 in mid-2026. Both agents are designed for once-yearly administration to enable population-scale prevention. Complementing the therapeutics, the company’s proprietary AI platform, Klotho, models lifetime ASCVD risk and quantifies the benefit of lowering LDL-C and blood pressure. The integrated approach aims to shift care from late-stage intervention to true prevention and extend healthspan. Corsera’s $80 million Series A financing provides the capital to advance these clinical programs and further develop the Klotho platform.

Total raised

$80M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2026